Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy.
AuthorsMitchell, Claire L
O'Connor, James P B
Parker, G J M
Buonaccorsi, G A
Clamp, Andrew R
Byrd, Louise M
Backen, Alison C
Jayson, Gordon C
AffiliationCancer Research UK, Department of Medical Oncology, Christie Hospital and University of Manchester.
MetadataShow full item record
AbstractBACKGROUND: Patients with recurrent ovarian cancer often achieve partial response following chemotherapy, resulting in persistent small volume disease. After completion of treatment, the dilemma of when to initiate subsequent chemotherapy arises. Identification of biomarkers that could be used to predict when subsequent treatment is needed would be of significant benefit. Design: Twenty-three patients with advanced ovarian cancer and residual asymptomatic disease following chemotherapy underwent dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) at study entry, 4, 8, 12, 18 and 26 weeks or disease progression. A subgroup of patients provided plasma samples within which a panel of angiogenic biomarkers was quantified. RESULTS: By 4 weeks, significant differences in whole tumour volume, enhancing fraction and Ca125 were observed between patients whose disease progressed by 26 weeks and those who remained stable. Significant correlations between plasma soluble vascular endothelial growth factor recptor-1 (sVEGFR-1) and sVEGFR-2 concentrations, and blood volume and tumour endothelial permeability surface area product measured by DCE-MRI were observed. CONCLUSIONS: Imaging markers have a potential role in early prediction of disease progression in patients with residual ovarian cancer and may supplement current measures of progression. The correlation of DCE-MRI and serological biomarkers suggests that tumour angiogenesis affects these markers through common biological means and warrants further investigation.
CitationIdentification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy. 2010: Ann Oncol
JournalAnnals of Oncology
- Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response.
- Authors: Levy T, Weiser R, Boaz M, Shem EB, Golan A, Menczer J
- Issue date: 2012 Oct
- Low-Grade Serous Carcinoma of the Ovary.
- Authors: Grisham RN
- Issue date: 2016 Jul
- A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
- Authors: Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Wouters MC, Kenter GG, van Erkel AR, van Poelgeest MI, Nijman HW, van der Hoeven JJ, Welters MJ, van der Burg SH, Kroep JR
- Issue date: 2015 Oct
- Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer.
- Authors: Mury D, Woelber L, Jung S, Eulenburg C, Choschzick M, Witzel I, Schwarz J, Jaenicke F, Mahner S
- Issue date: 2011 Jul
- Chronic administration of single weekly paclitaxel in heavily pretreated ovarian cancer patients.
- Authors: Yamamoto K, Oogi S, Inoue H, Kudoh K, Kita T, Kikuchi Y
- Issue date: 2004 Feb